Eurofins-Cerep SA
ALECR
Company Profile
Business description
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
Contact
Le bois l Eveque
Celle l Evescault86600
FRAT: +33 549893000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
207
Stocks News & Analysis
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,927.60 | 14.00 | 0.16% |
| CAC 40 | 8,150.64 | 64.59 | 0.80% |
| DAX 40 | 24,199.50 | 238.91 | 1.00% |
| Dow JONES (US) | 47,951.85 | 65.88 | 0.14% |
| FTSE 100 | 9,837.77 | 63.45 | 0.65% |
| HKSE | 25,498.13 | 29.35 | 0.12% |
| NASDAQ | 23,006.36 | 313.04 | 1.38% |
| Nikkei 225 | 49,001.50 | 510.78 | -1.03% |
| NZX 50 Index | 13,312.89 | 56.12 | 0.42% |
| S&P 500 | 6,774.76 | 53.33 | 0.79% |
| S&P/ASX 200 | 8,636.60 | 15.10 | 0.18% |
| SSE Composite Index | 3,876.37 | 6.09 | 0.16% |